Clinical and Translational Neuroscience (Dec 2022)
Saudi Consensus Recommendations on the Management of Multiple Sclerosis: Disease-Modifying Therapies and Management of Relapses
- Yaser M. Al Malik,
- Ibtisam A. Al Thubaiti,
- Maha A. AlAmmari,
- Norah Al Fugham,
- Eman N. Ali,
- Dema A. Alissa,
- Salman A. Aljarallah,
- Ahmed H. Al-Jedai,
- Maeed A. AlKathiri,
- Mona M. AlKhawajah,
- Mousa A. Almejally,
- Hajer Y. Al-Mudaiheem,
- Hessa S. Al Otaibi,
- Ghadah H. AlTowaijri,
- Rumaiza H. Al Yafeai,
- Mohammed A. Babakkor,
- Saeed A. Bohlega,
- Reem F. Bunyan,
- Edward J. Cupler,
- Mohammed Hakami,
- Abid M. Kareem,
- Amr M. Khardaly,
- Seraj Makkawi,
- Leena H. Saeed,
- Jameelah A. Saeedi,
- Eslam Shosha,
- Mohammad A. Al Jumah
Affiliations
- Yaser M. Al Malik
- College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Prince Mutib Ibn Abdullah Ibn Abdulaziz Rd, Ar Rimayah, Riyadh 14611, Saudi Arabia
- Ibtisam A. Al Thubaiti
- Department of Neurology, King Fahad Military Medical Complex Dhahran, Abqaiq Road, Dhahran 31932, Saudi Arabia
- Maha A. AlAmmari
- College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Prince Mutib Ibn Abdullah Ibn Abdulaziz Rd, Ar Rimayah, Riyadh 14611, Saudi Arabia
- Norah Al Fugham
- Neurology Department, King Faisal Specialist Hospital and Research Center, Al Mathar Ash Shamali, Makkah Al Mukarramah Branch Road, Riyadh 11564, Saudi Arabia
- Eman N. Ali
- Department of Neurology, King Fahad Specialist Hospital Dammam, Ammar Bin Thabit Street, Dammam 32253, Saudi Arabia
- Dema A. Alissa
- Deputyship of Therapeutic Affairs, Ministry of Health, An Nakheel, Riyadh 12382, Saudi Arabia
- Salman A. Aljarallah
- Department of Medicine, King Saud University, Riyadh 12372, Saudi Arabia
- Ahmed H. Al-Jedai
- Deputyship of Therapeutic Affairs, Ministry of Health, An Nakheel, Riyadh 12382, Saudi Arabia
- Maeed A. AlKathiri
- Neurology Unit, Medical Department, Aseer Central Hospital, Prince Sultan Bin Abdulaziz Street, Abha 62523, Saudi Arabia
- Mona M. AlKhawajah
- Department of Neurosciences, King Faisal Specialist Hospital and Research Center, Al Mathar Ash Shamali, Makkah Al Mukarramah Branch Road, Riyadh 11564, Saudi Arabia
- Mousa A. Almejally
- Department of Neurology, Heraa General Hospital, Al Buhayrat, Makkah 9364, Saudi Arabia
- Hajer Y. Al-Mudaiheem
- Deputyship of Therapeutic Affairs, Ministry of Health, An Nakheel, Riyadh 12382, Saudi Arabia
- Hessa S. Al Otaibi
- Neurology Unit, Department of Medicine, King Fahad Hospital, Al Mustashfa Al Am Al Andalus, Jeddah 23325, Saudi Arabia
- Ghadah H. AlTowaijri
- National Neuroscience Center, King Fahad Medical City, As Sulimaniyah, Riyadh 12231, Saudi Arabia
- Rumaiza H. Al Yafeai
- Department of Neurology, Psychiatry and Psychology, My Clinic International Medical Co., Prince Sultan Road Al Mohammadiyyah, Jeddah 23617, Saudi Arabia
- Mohammed A. Babakkor
- Neuroscience Center, Neurology Department, King Abdullah Medical City, Ministry of Health, Muzdalifah Road Al Mashair, Makkah Al-Mukarramah 24246, Saudi Arabia
- Saeed A. Bohlega
- Department of Neurosciences, King Faisal Specialist Hospital and Research Center, Al Mathar Ash Shamali, Makkah Al Mukarramah Branch Road, Riyadh 11564, Saudi Arabia
- Reem F. Bunyan
- Department of Neurology, King Fahad Specialist Hospital Dammam, Ammar Bin Thabit Street, Dammam 32253, Saudi Arabia
- Edward J. Cupler
- Department of Neurosciences, King Faisal Specialist Hospital and Research Center, Al Shoubasi Ar Rawdah, Jeddah 23431, Saudi Arabia
- Mohammed Hakami
- Neurology Unit, King Fahad Central Hospital, Abu Arish Road, Jazan 140, Saudi Arabia
- Abid M. Kareem
- Department of Neurology, King Fahad Hospital Al Jamiah, Khaleb Ibn Al Walid Branch Road, Madinah 42351, Saudi Arabia
- Amr M. Khardaly
- Deputyship of Therapeutic Affairs, Ministry of Health, An Nakheel, Riyadh 12382, Saudi Arabia
- Seraj Makkawi
- College of Medicine, King Saud bin Abdulaziz University for Health Sciences, Mecca Jeddah highway, Jeddah 22384, Saudi Arabia
- Leena H. Saeed
- Department of Pharmacy, King Fahad Medical City, Prince Abdulaziz Ibn Musaid Ibn Jalawi Street, Riyadh 12231, Saudi Arabia
- Jameelah A. Saeedi
- Department of Neurology, King Abdullah Bin Abdulaziz University Hospital, King Khalid International Airport Road, Riyadh 11564, Saudi Arabia
- Eslam Shosha
- Division of Neurology, Department of Medicine, McMaster University, 1280 Main St W, Hamilton, ON L8S 4L8, Canada
- Mohammad A. Al Jumah
- Department of Neurology, King Fahad Medical City, Riyadh 11525, Saudi Arabia
- DOI
- https://doi.org/10.3390/ctn6040027
- Journal volume & issue
-
Vol. 6,
no. 4
p. 27
Abstract
For the past 10 years, disease-modifying therapy (DMT) options for multiple sclerosis (MS) have grown remarkably where DMTs have been shown to reduce the risk of MS relapses. MS patients are advised to begin treatment with a DMT shortly after diagnosis to limit the possibility of disease progression over time. While patients with radiologically isolated syndrome do not require pharmacologic treatment, high-risk patients with clinically isolated syndrome are advised to start DMTs. This article provides evidence-based recommendations for DMT use in MS management, helping healthcare practitioners advise patients on treatment decisions. We aim to provide recommendations for the management of acute MS relapses. The recommendations herein were developed following the gathering of a panel of experts after evaluating international guidelines, and the latest evidence was collected through a comprehensive literature review.
Keywords
